MedTrace Logo

Safety Study of Combined Chemotherapy and Endostar to Untreated Patients With Advanced Melanoma

NCT00813449 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 140

Last updated 2009-12-08

No results posted yet for this study

Summary

Multicenter, double-blinding, randomized controlled, phase II clinical trial on combined chemotherapy of Endostar (Recombinant Human Endostatin) for untreated patients with advanced melanoma, To compare the efficacy and safety of Endostar combined with Dacarbazine and monotherapy of Dacarbazine for advanced melanoma

Conditions

Interventions

DRUG

dacarbazine plus Endostar (Experimental group)

dacarbazine plus Endostar

DRUG

dacarbazine plus placebo (control group)

dacarbazine plus placebo

Sponsors & Collaborators

  • Simcere Pharmaceutical Co., Ltd

    lead OTHER

Principal Investigators

  • Guo Jun, PI · Expert Committee for Melanoma of CSCO

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-08-31
Primary Completion
2010-08-31
Completion
2010-08-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00813449 on ClinicalTrials.gov